ANNEX I

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANT, MARKETING

AUTHORISATION HOLDER IN THE MEMBER STATES

1

Member State EU/EEA

Marketing authorisation holder

Applicant (Invented) Name

Strength Pharmaceutical form

Route of administration

Content (concentration)

Ireland

CHX Technologies Europe Limited Guinness Enterprise Centre Taylor’s Lane Dublin 8, Ireland

Prevora 100 mg/ml Dental Solution

100 mg per ml solution

Dental solution Dental use (supra-gingival to the hard tissue only)

100 mg/ml

United Kingdom

CHX Technologies Europe Limited Guinness Enterprise Centre Taylor’s Lane Dublin 8, Ireland

Prevora 100 mg/ml Dental Solution

100 mg per ml solution

Dental solution Dental use (supra-gingival to the hard tissue only)

100 mg/ml

2

ANNEX II

SCIENTIFIC CONCLUSIONS AND GROUNDS FOR POSITIVE OPINION AND AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EUROPEAN MEDICINES AGENCY

3

Scientific conclusions

Overall summary of the scientific evaluation of Prevora

Dental caries is a bacterial based chronic disease. The medicinal product, Prevora 100 mg/ml is a 10% w/v chlorhexidine dental solution indicated to reduce dental caries in permanent teeth of adolescents and adults. The product is a topical two-stage chlorhexidine solution. It consists of a chlorhexidine coating solution (Stage 1) and an inert sealant coating (Stage 2) which is applied after the application of the chlorhexidine solution. It is intended to be applied to the surface of permanent teeth in four weekly applications in the first month of treatment, followed by a single application at month six. Subsequent applications being based upon clinical judgment of caries risk by the dental professional.

Prevora has been evaluated in two randomised, double-blinded, placebo-controlled clinical trials (RCTs) conducted according to GCP. The two clinical studies initially submitted by the MAH to support the proposed indication were:

Clinical Study #001 (Adult Xerostomia Study)

A double-blind, randomised, multi-centred, controlled trial conducted in adults at risk of dental caries. The pivotal study included a total of 79 subjects on active.

The comparison of caries increment was active versus placebo. A 24.5% reduction for all tooth surfaces (root plus coronal surfaces) was seen with a p-value of 0.0322 [95% confidence interval (CI) of 0.62 – 0.98]. For root surfaces, a 40.8% reduction with a p-value 0.0206 (95% CI of 0.23 – 0.78) and for coronal surfaces, no significant difference was seen between placebo and Prevora (p-value 0.0644).

The results were considered not compelling enough due to the unsupportive nature of the adolescent study (below). Clinical Study #002 (Dundee Adolescent Study)

A 3-year randomised double-blind trial in at-risk adolescent patients to evaluate the efficacy and safety of Prevora 100mg/ml Dental Solution in reducing caries increment. These were patients between the ages of 11 and 13 years with evidence of past or current caries experience and elevated levels of salivary Streptococcus mutants. This study was submitted as supportive data since it was a failed study, as no significant difference was found between placebo and Prevora as measured by the primary outcome variable. The positive results seen in this study relate only in the female subgroup which was not based on a pre-defined subgroup analysis but a post-hoc analysis. Therefore, these results do not provide robust evidence of efficacy. The objecting Member State was of the view that the evidence provided was not considered compelling enough even in the high-risk adult population. The MAH, CHX Technologies Europe Ltd submitted to CHMP for consideration the results of another study, the Prevention of Adult Caries Study (PACS), to confirm the results seen to date.

Prevention of Adult Caries Study (PACS)

This is a Phase III, multi-centre, placebo-controlled, double-blinded, prospective study. The study enrolled 983 at-risk adults and the study objectives were: determine the efficacy of Prevora in reducing cavities in at-risk adults, evaluate its safety, and evaluate the emergence if any, of chlorhexidine-resistant Streptococcus mutans post treatment in study participants, and the emergence, if any, of opportunistic infections in the form of Candida albicans post treatment in study participants.

The primary endpoint was the number of new cavities (coronal plus root surfaces) per participant, as measured at the end-of-study visit. The secondary endpoints were new coronal cavities and root cavities per participant.

4

The study population consisted of 983 adults ranging in age from 18 and 80 years and with a mean age of 43 years. This study population is considered representative of the patients in the EU.

As defined by the primary endpoint, this study showed no significant difference between active and placebo. Therefore, Prevora appears to have a negative effect, resulting in more cavities in the at low-risk population. The CHMP assessing the apparent “reverse” treatment effect for at low-risk population explained this issue by the relative absence of high risk participants (those with 3+ cavities at screening) in the placebo groups where as the high-risk population (at risk population) had a higher baseline rate of cavities.

When risk (as measured by the number of cavities at screening) is added to the ANOVA model to account for the bimodal distribution of disease in this study population at both screening and during the study, an overall clinical effect of 36.8% at p = 0.04 is observed. The significance of this preventive effect increases for high risk participants, for both all tooth surfaces and for coronal surfaces. There is no evidence of a difference in the point estimates for coronal and all surfaces which suggest that the results for root surfaces should be of a similar magnitude. Although the results may not be statistically significant, there was no evidence of an interaction, and thus there are sufficient statistical evidence to grant an indication for all surfaces in the high-risk population, and not just root surfaces.

Considering the resistant and opportunistic infections, this study showed no significant resistance to Streptococcus mutans or opportunistic infections with Candida albicans after treatment with Prevora over one year in adult patients.

This study did not raise any concern in terms of safety.

Benefit-risk assessment

The PACS study failed on the primary endpoint as there was no difference between active and placebo in the number of caries per patient. However, when the result in high-risk patients is considered, a significant difference is seen between active and placebo. Therefore, when considered in addition to the previously submitted data, there is now sufficient evidence to conclude that the risk-benefit is positive in the proposed indication. In addition, the new trial also suggests a benefit for coronal surfaces, and no apparent differences between root and coronal surfaces.

It was concluded that the indication in patients at high-risk should be maintained and that the result seen with coronal surfaces should also be reflected. The following indication was agreed by the CHMP:

‘Prevora 100mg/ml Dental Solution is an antiseptic solution which is applied topically to the dentition of patients for the prevention of coronal and root caries in adult patients at high-risk of dental caries (e.g. xerostomia sufferers or those with 3 or more caries at the start of the treatment plan). To be used in dental offices only by dental professionals.’

Furthermore, it was agreed that the product information should also be amended to reflect that no significant resistance to Streptococcus mutans or opportunistic infections with Candida albicans were observed after treatment with Prevora over one year in adult patients.

5

6

Grounds for positive opinion and amendment of the summary of product characteristics and package leaflet

Whereas,

the assessment of all available data submitted by the MAH in particular the result from the PACS in high risk patients;

and scientific discussion within the Committee

the CHMP has recommended the granting of the marketing authorisation for which the summary of product characteristics and package leaflet are set out in Annex III for Prevora

ANNEX III

SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET

Note: This SPC, labelling and packages leaflet is the version valid at the time of Commission decision.

After the Commission decision the Member State competent authorities, in liaison with the reference Member State, will update the product information as required. Therefore, this SPC, labelling and

package leaflet may not necessarily represent the current text.

7

SUMMARY OF PRODUCT CHARACTERISTICS

8

The valid summary of product characteristics is the final version achieved during the Coordination group procedure with the following amendments:

9

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Prevora 100mg/ml Dental Solution.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 1 ml of Prevora Dental Solution (Stage 1 chlorhexidine coating) contains chlorhexidine diacetate 100mg For a list of full excipients, see section 6.1

3. PHARMACEUTICAL FORM

Dental Solution Stage 1 chlorhexidine coating A clear, slightly brownish solution with a characteristic odour, free of visible particulate matter. Stage 2 sealant coating A milky-white liquid of low viscosity with a faint characteristic odour, free of visible particulate matter. 4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Prevora 100mg/ml Dental Solution is an antiseptic solution which is applied topically to the dentition of patients for the prevention of root coronal and root caries in adult patients at high-risk of dental caries (e.g. xerostomia sufferers or those with 3 or more caries at the start of the treatment plan). To be used in dental offices only by dental professionals. Patients should be advised on the importance of oral hygiene and sugar intake: In the case of patients with poor oral hygiene and/or frequent consumption of sugars, advise the patient that regular and frequent tooth brushing with fluoridated tooth paste, combined with controlling sugar intake, are important to the overall success of treatment.

4.2 Posology and method of administration

Posology An individual dosing in adults is between 300 µl and 600 µl of Prevora 100 mg/ml Dental Solution. The patient is to receive 5 treatments in the initial year of treatment, of which 4 are administered one week apart in the first month, and the final dose is administered at 6 months. Treatment of the dental patient thereafter is according to professional clinical judgment of the risk of dental caries. Prevora 100 mg/ml Dental Solution is administered topically to the entire dentition of the patient using a cotton pellet or fine paint brush. The cotton pellet or brush is dipped into the Prevora 100 mg/ml Dental solution and thereafter is applied to the tooth surfaces (Figure 1).

10

Figure 1 Application of Prevora 100 mg/ml Dental Solution

Dip cotton pellet or fine brush in vial and then apply pellet or brush to tooth surfaces.

The patient should be instructed that: The dried Prevora coating will begin coming off the teeth during the next meal. They should avoid eating hard foods (e.g. meat, apples) for at least 4 hours after

treatment Do not chew gum for at least 24 hours. Do not brush his/her teeth for 24 hours after treatment. Then to resume brushing with

a new brush 2 to 3 times daily with fluoride tooth paste. Do not floss for 3 days after treatment. Then to resume flossing daily. If dentures are worn, clean and disinfect these dentures regularly prior to use.

Disinfect using soap and warm water.

Method of administration External (oral) topical use in the dental office by a dental professional. This product is not intended to be swallowed. 4.3 Contraindications Hypersensitivity to chlorhexidine, Sumatra benzoin or ethanol. 4.4 Special warnings and precautions for use For external (oral) topical use only – keep out of the eyes and ears. If the drug product comes into contact with the eyes, wash out promptly and thoroughly with water. Prevora 100 mg/ml Dental Solution should be used with caution in patients with a history of asthma or eczema. Avoid application of Prevora 100 mg/ml Dental Solution to the soft tissues. Failure to do so can result in temporary stinging or mild inflammation of the soft tissues. 4.5 Interaction with other medicinal products and other forms of interaction Prevora 100 mg/ml Dental Solution should not be applied immediately following use of an oil-based prophylactic paste or up to 3 days following application of a fluoride dental varnish. Chlorhexidine is incompatible with anionic agents. 4.6 Fertility, pregnancy and lactation No controlled studies have been carried out to ascertain if there are any adverse reactions when Prevora 100 mg/ml Dental Solution is applied to the dentition of women of childbearing potential, or to the dentition of expectant or breast feeding mothers. Therefore, it is recommended that Prevora 100 mg/ml Dental Solution should not be administered during pregnancy. Since many drugs are excreted during lactation and there have not been any studies performed using Prevora 100 mg/ml Dental

11

Solution in nursing mothers, it is recommended that Prevora 100 mg/ml Dental Solution should not be applied if the mother is nursing. 4.7 Effects on ability to drive and use machines No studies on the effects on the ability to drive and use machines have been performed. 4.8 Undesirable effects Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Uncommon (≥1/1,000 to <1/100)

Not known (cannot be estimated from the available data)

Skin and subcutaneous tissues disorders

Redness and/or temporary stinging sensation of the oral mucosa Objectionable, bitter taste when Prevora 100 mg/ml Dental Solution comes into contact with the saliva or oral mucosa

Immediate hypersensitivity reactions to chlorhexidine (urticaria or anaphylaxis)

General disorders and administration site conditions

Transient tooth sensitivity and loss of taste Discoloration of the teeth and silicate or composite restorations

4.9 Overdose There is no experience with over-dosage with Prevora 100 mg/ml Dental Solution. Consequently, the signs and symptoms have not been identified. If overdose should occur, treat symptomatically. 5. PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: A01AB Anti-infectives and antiseptics for local oral treatment. ATC Code: A01AB03 chlorhexidine. Chlorhexidine is effective against a wide range of important oral microorganisms associated with dental caries. Chlorhexidine in the drug product has been found at bactericidal levels to Streptococcus mutans for between 24 hours and 48 hours on the surface of adult dental patients after its application, as measured by HPLC. There have been no published reports of permanent resistance by Streptococcus mutans to the repeated use of chlorhexidine for up to 2 years and no significant resistance to Streptococcus mutans or opportunistic infections with Candida albicans were observed after treatment with Prevora over one year in adult patients. The cumulative monthly mean dose of chlorhexidine delivered by Prevora 100 mg/ml Dental Solution is approximately equal to that of 1.0% w/w chlorhexidine dental gel and approximately half that of 0.2% w/v chlorhexidine oral rinse.

5.2 Pharmacokinetic properties

12

Chlorhexidine binds strongly to the oral mucosa and the dentition and thus has very poor systemic absorption. No detectable blood levels of chlorhexidine have been found after oral use. 5.3 Preclinical safety data

Preclinical data reveal no special hazard for humans.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients Stage 1 chlorhexidine coating: Sumatra benzoin Ethanol Stage 2 sealant coating: Ammonio methacrylate copolymer dispersion,Type B Triethyl citrate 6.2 Incompatibilities In the absence of compatibility studies, this topical medicinal product must not be mixed with other topical medicinal products. 6.3 Shelf life 18 months. Discard any remaining solution immediately after use. 6.4 Special precautions for storage Store in refrigerator (2º to 8ºC) 6.5 Nature and contents of container Prevora 100 mg/ml Dental Solution contains: Stage 1 chlorhexidine coating: Chlorhexidine diacetate Sumatra benzoin Ethanol Stage 2 sealant coating: Ammonio methacrylate copolymer dispersion, Type B Triethyl citrate One treatment box of Prevora Dental solution contains 6 Type 1 glass vials of Stage 1 chlorhexidine coating along with 6 Type 1 glass vials of Stage 2 sealant coating.

6.6 Special precautions for disposal and other handling

Step #1. Preparation: Ensure that the dentition contains no open caries lesions or restorations with imperfect margins. Prepare for the application with a tray (Figure 2), consisting of cotton rolls, cotton pellets or fine brushes, forceps, air syringe, and a vial of Stage 1 chlorhexidine coating and a vial of Stage 2 sealant coating.

13

Figure 2: Tray set up for Stage One Stage 1 chlorhexidine coating and Stage 2 sealant coating treatments.

Step #2. Prophylaxis: Give a rubber cup prophylaxis using flour of pumice and water. Avoid using a non-oil based prophylactic paste. Step #3. Floss: Thoroughly rinse and floss the patient’s teeth with un-waxed floss to remove pumice and residual dental plaque. Ensure the cleanliness of the distal surface of the last tooth in each arch by wiping it with a cotton pellet held in a pair of forceps. Step #4. Isolate one quadrant: Isolate one quadrant of the dentition with cotton rolls and a saliva ejector. Step #5. Dry teeth: Dry all teeth in that quadrant with an air syringe. Step #6. Apply Stage 1 chlorhexidine coating inter-proximally: Using a cotton pellet held in forceps, or a fine brush suitable for reaching inter-proximal areas, apply Stage 1 Chlorhexidine coating to the inter-proximal areas of all posterior teeth in the quadrant, ensuring not to apply the coating to the soft tissues. Then dry these tooth surfaces with an air syringe.

Figure 3: Apply Prevora Stage 1 chlorhexidine coating with a fine brush to the gingival margin, followed by Prevora Stage 2 sealant coating using the same techniques. Step #7. Apply Stage 1 chlorhexidine coating to other tooth surfaces: Apply this coating to all other tooth surfaces (Figure 3) in this same quadrant, and then air dry. Be careful to avoid applying Stage 1 chlorhexidine coating to the soft tissues as the patient may experience stinging or burning of the gums or tongue. Step #8. Apply Stage 2 sealant coating: Apply this second coating (with white cap), using a second cotton pellet or with another fine brush, to this same quadrant. Then dry this second coating with an air syringe. Step #9. Repeat coating of other quadrants: Repeat steps 4 through 8 in the remaining quadrants of the dentition. Step #10. Advise the patient: Instruct the patient:

The dried Prevora coating will begin coming off the teeth during the next meal. To avoid eating hard foods (e.g. meat, apples) for at least 4 hours after treatment. Do not chew gum for at least 24 hours. Do not brush his/her teeth for 24 hours after treatment. Then to resume brushing

with a new brush 2 to 3 times daily with fluoride tooth paste. Do not floss for 3 days after treatment. Then to resume flossing daily. If dentures are worn, clean and disinfect these dentures regularly prior to use.

Disinfect using soap and warm water.

14

Step #11. Schedule repeat treatments: Repeat this initial Prevora application every week for 3 more weeks after the initial application, followed by a single application at six months and thereafter according to clinical judgment. Instruments and clothing in contact with Stage 1 chlorhexidine coating may be cleaned with alcohol. Instruments and clothing in contact with Stage 2 sealant coating may be cleaned with water.

Any unused product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

CHX Technologies Europe Limited Guinness Enterprise Centre Taylor’s Lane Dublin 8 Ireland 8. MARKETING AUTHORISATION NUMBER(S) PA 1205/1/1 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of First Authorisation: 5th May 2006. 10. DATE OF REVISION OF THE TEXT September 2010 Detailed information on this medicinal product is available on the website of

15

LABELLING

16

The valid labelling is the final version achieved during the Coordination group procedure:

17

PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON 1. NAME OF THE MEDICINAL PRODUCT Prevora 100 mg/ml Dental Solution Chlorhexidine diacetate 2. STATEMENT OF ACTIVE SUBSTANCE(S) Each 1 ml of Prevora Dental Solution (Stage 1 chlorhexidine coating) contains chlorhexidine diacetate 100 mg. 3. LIST OF EXCIPIENTS Stage 1: sumatra benzoin and ethanol Stage 2: ammonio methacrylate copolymer dispersion, Type B and triethyl citrate 4. PHARMACEUTICAL FORM AND CONTENTS Dental solution Treatment sets consist of: 6 vials of Stage 1 chlorhexidine coating in a 2 ml Type 1 glass vial 6 vials of Stage 2 sealant coating in a 2 ml Type 1 glass vial 5. METHOD AND ROUTE(S) OF ADMINISTRATION Read the package leaflet before use. For external (oral) topical use only. 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT

OF THE REACH AND SIGHT OF CHILDREN Keep out of the reach and sight of children. 7. OTHER SPECIAL WARNING(S), IF NECESSARY Not applicable 8. EXPIRY DATE EXP 9. SPECIAL STORAGE CONDITIONS Store upright in a refrigerator at 2° - 8° C. 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

18

CHX Technologies Europe Limited Guinness Enterprise Centre Taylor’s Lane Dublin 8, Ireland 12. MARKETING AUTHORISATION NUMBER(S) <[To be completed nationally]> 13. BATCH NUMBER Lot 14. GENERAL CLASSIFICATION FOR SUPPLY <[To be completed nationally]> 15. INSTRUCTIONS ON USE Read the package leaflet before use. 16. INFORMATION IN BRAILLE <Justification for not including Braille accepted>

19

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL – 2ml 1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Stage 1 Chlorhexidine coating 100 mg/ml Dental solution, chlorhexidine diacetate Stage 2 Sealant coating 2. METHOD OF ADMINISTRATION Dental use 3. EXPIRY DATE MM/YYYY 4. BATCH NUMBER LOT 5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT Each vial contains 1 ml of stage 1 chlorhexidine coating 6. OTHER

MA #

Read the package leaflet before use.

20

PACKAGE LEAFLET

21

The valid package leaflet is the final version achieved during the Coordination group procedure with the following amendments:

22

PACKAGE LEAFLET: INFORMATION FOR THE USER

Prevora 100 mg/ml Dental Solution Chlorhexidine diacetate

Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have further questions, please ask your dental professional. This coating has been recommended for your teeth by your dental professional and will be applied

to your teeth by your dental professional on several occasions. If any of the side effects get serious, or if you notice any side effects not listed in this leaflet,

please tell your dental professional.

In this leaflet 1. What Prevora is and what it is used for. 2. Before you are treated with Prevora. 3. How you are treated with Prevora. 4. Possible side effects. 5. How to store Prevora. 6. Further information.

1. WHAT PREVORA IS AND WHAT IT IS USED FOR This dental coating is a topical treatment for the prevention of cavities on the crown and the root of the tooth of adult patients at high-risk of tooth decay (e.g. dry mouth sufferers or those with a number of cavities when you visit the dentist). This coating temporarily covers your teeth to reduce the bacteria on your teeth which cause tooth decay. Oral hygiene and sugar intake: If you have poor oral hygiene and/or you frequently consume sugars you need to make sure you brush your teeth with fluoridated tooth paste and control your sugar intake, as they are important contributors to the overall success of Prevora. 2. BEFORE YOU ARE TREATED WITH PREVORA Do not be treated with Prevora • If you are allergic to chlorhexidine, Sumatra benzoin or ethanol. • If you are allergic to the ingredients of the Stage 2 sealant, which is a secondary coating applied

immediately over Stage 1. The ingredients of this second coating are methacrylate, triethyl citrate and purified water.

• If you have been treated with a fluoride dental varnish in the past 3 days.

Take special care with Prevora before undergoing treatment with Prevora, to report your medical condition including asthma,

eczema and other allergies, to your dentist. Taking other medicines Please inform your dental professional if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Pregnancy and breast-feeding Ask your dentist for advice before taking or receiving any medicine. Driving and using machines Prevora has not been shown to affect driving. Prevora has not been shown to affect the use of machines. Important information about some of the ingredients of Prevora

23

This dental coating can cause a temporary irritation or stinging of the gums, lips or tongue and can also have a bitter taste. Chlorhexidine, the active substance in Prevora, can also cause staining of the teeth; however, when chlorhexidine is applied as a topical, temporary dental coating, staining is rare. 3. HOW YOU ARE TREATED WITH PREVORA This topical, temporary coating on your teeth is applied by your dental professional in a short appointment in the dental office. The dental professional will first clean your teeth, and then apply Stage 1 to all tooth surfaces (Figure 1), followed immediately by a second coating of Stage 2. This second coating temporarily protects Stage 1 from your saliva and from food abrasion.

Figure 1 – Stage 1 followed by a second coating will be applied to your teeth so as to reduce your risk of tooth decay. At the start of your treatment with Prevora , you will require 4 weekly treatments followed by another single treatment in 6 months. Thereafter, your need for more treatments with Prevora will be evaluated by your dental professional. You will be told by your Dental Professional that:

The dried Prevora coating will begin coming off the teeth during the next meal You should avoid eating hard foods (e.g. meat, apples) for at least 4 hours after treatment. You should not chew gum for at least 24 hours. You should not brush your teeth for 24 hours after treatment. Then you resume brushing with

a new brush 2 to 3 times daily with fluoride tooth paste. You should not floss for 3 days after treatment. Then you resume flossing daily. If dentures are worn, clean and disinfect these dentures regularly prior to use. Disinfect using

soap and warm water. Effects when the Prevora treatment is finished Temporarily, you may have a bitter taste, a sensation of a coating on your teeth and/or a stinging or burning along your gum line or tongue. The stinging will last for a few minutes, the coating for a few hours. The coating will be invisible on your teeth. Chlorhexidine, the active substance in Prevora , can stain the teeth when used in a mouth rinse or gel; however, in controlled clinical studies and dental office use, the occurrence of tooth staining by the Prevora dental coating is rare. If staining occurs it is not permanent and can largely be eliminated by brushing with a conventional fluoridated toothpaste, once tooth brushing re-commences 24 hours after treatment with Prevora. A professional cleaning will remove any staining but if conducted within 7 days of treatment will also minimize the effect of Prevora. If you receive a professional cleaning, it should be done 7 days after the Prevora treatment.

24

What to do after you are treated with Prevora To preserve this coating on your teeth for as long as possible, eat soft foods at your next meal (e.g. soup). Do not eat hard foods (e.g. meat, apples) for at least 4 hours after treatment. Do not chew gum for at least 24 hours. Do not brush your teeth for 24 hours after this treatment. Then resume brushing with a new tooth brush and brush 2 to 3 times daily with fluoride toothpaste. Do not floss your teeth for 3 days following this treatment. Then resume flossing daily. If dentures are worn, clean and disinfect at home prior to use. Disinfect using soap and warm water. Make sure you receive all the treatments of Prevora, recommended by your dentist. It is an important contribution to the overall success of this treatment, that you regularly brush your teeth with a fluoridated tooth paste, and that you control your consumption of foods and drinks which have a high amount of sugar and acid. If you have any further questions on the use of this product, ask your dental professional. 4. POSSIBLE SIDE EFFECTS Like all medicines, Prevora can cause side effects, although not everybody gets them. If you have prolonged stinging or burning of the gums, lips or tongue, you should see your dental professional as soon as possible. If your teeth appear stained after treatment with Prevora, please inform your dental professional. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your dental professional. 5. HOW TO STORE PREVORA Keep out of the reach and sight of children. Do not use Prevora after the expiry date which is stated on the carton and single vial labels after EXP. The expiry date refers to the last day of that month. Discard any remaining solution immediately after use. Prevora should be stored in a refrigerator (2ºC - 8ºC) at your dental professional’s office. Medicines should not be disposed of via wastewater or household waste. These measures will help to protect the environment. 6. FURTHER INFORMATION What Prevora contains: Stage 1 chlorhexidine coating: 100 mg/ml Dental Solution The active substance is Chlorhexidine diacetate. The other ingredients are Sumatra benzoin and Ethanol

25

26

Stage 2 sealant coating: The ingredients are Ammonio methacrylate copolymer dispersion, Type B and Triethyl citrate What Prevora looks like and contents of the pack: Dental Solution The chlorhexidine coating is a clear, slightly brownish solution with a noticeable scent, free of any floating particles in the solution. The sealant coating is a milky-white liquid with a faint scent Each treatment set of Prevora 100 mg/ml Dental Solution consists of: 6 vials of Stage 1 chlorhexidine coating in a 2 ml Type 1 glass vial 6 vials of Stage 2 sealant coating in a 2 ml Type 1 glass vial Marketing Authorization Holder and Manufacturer Marketing Authorization Holder: CHX Technologies Europe Limited Guinness Enterprise Centre Taylor’s Lane Dublin 8, Ireland Tel: (01) 4100600 Manufacturer: United Drug Plc United Drug House Magna Drive, Magna Business Park Citywest Road Dublin 24, Ireland Tel (353) 1 463 2300 This leaflet was last approved in Detailed information on this medicinal product is available on the website of